



en-GB

INTENDED PURPOSE

Optitrol NAT HBV Screening is a quality control (QC) sample intended to monitor the performance of *in-vitro* assays which are used for screening human blood, serum and plasma for presence of hepatitis B virus (HBV) DNA. This QC was manufactured as a positive control and may be helpful in determining the precision of testing systems and in identifying sources of variation. Optitrol NAT HBV Screening is an unassayed extraction and amplification control without target values. This control must not be used as a substitute for the mandatory manufacturer's kit controls provided with the assay.

Optitrol NAT HBV Screening is an *in-vitro* diagnostic medical device for professional use.

CONTENTS

Optitrol NAT HBV Screening contains human serum as a major component which was tested and found negative/nonreactive for anti-HIV 1/2, anti-HCV and HBsAg. The control was manufactured using human plasma with intact hepatitis B viruses, which were inactivated by gamma radiation. Optitrol NAT HBV Screening controls are traceable to 3rd WHO International Standard for HBV (10/264).

Examples of possible reactivity (no target values) for this control can be found at <http://www.seracare.com/resourcelibrary>. Users of Optitrol QC samples have access to EDCNet, an Internet-based QC results monitoring system at <https://www.nrlquality.org.au/products-services/qconnect>.

STORAGE AND STABILITY

Optitrol NAT HBV Screening:

- Stable until the expiration date when stored at -40 °C to -20 °C.
- Stable after thawing for 5 days when stored at 2 °C to 8 °C.
- Stable for 24 hours once opened provided it is closed tightly after use and returned to storage at 2 °C to 8 °C.
- Do not dilute.
- Always store vials upright.
- Do not use beyond the expiration date.

INSTRUCTIONS FOR USE

- Thaw at room temperature and use immediately or store at 2 °C to 8 °C.
- Mix contents briefly by vortexing before opening.
- After use, the control may be stored at 2 °C to 8 °C for up to 24 hours.
- Optitrol NAT HBV Screening should be treated using the same procedure as a patient sample, including the extraction and amplification steps.
- Follow the assay manufacturer's instructions for use.
- The expected values when using the control must be determined by the user for the respective HBV assay.

LIMITATIONS

- Do not use this product if there is evidence of microbial contamination and/or high turbidity.
- Deviation from the recommended procedure may lead to unreliable results.
- This product is provided for quality assurance only and should not be used for calibration purposes.
- This product is not automated.
- Possible causes of variation in performance:
 - Different assay reagent lots.
 - Different calibrator lots used.
 - Different analysers used.
 - Different operators.
 - Time of day when testing.

PRECAUTIONS AND DISPOSAL INFORMATION

- Optitrol NAT HBV Screening is for *in-vitro* diagnostic use only and should be tested by trained personnel only.
- Optitrol NAT HBV Screening contains materials of human origin and should be considered potentially infectious. Observe universal precautions and handle this control like a patient sample.
- Wear protective gloves/ protective clothing.
- Do not pipette by mouth.
- Discard all materials in a safe manner that is in compliance with local and national regulations and in accordance with laboratory procedure for disposal of clinical waste.

REFERENCES

- Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
- For further information, please refer to the appropriate instructions for use of the assays used.

For assistance, contact LGC Clinical Diagnostics Technical Support at +1 508.244.6400 / CDx-Info@LGCGroup.com.

Any serious incident that has occurred in relation to the device shall be reported to LGC Clinical Diagnostics Technical Support and, if in use in the EU, the competent authority of the Member State in which the incident occurred.

| Date | Description of Change |
|------------|-----------------------|
| March 2026 | Update for IVDR |

REF PACKAGE SIZE

| Reference No. | Package size |
|---------------|----------------------|
| NT01011 | 5 x 1.2 mL Positive |
| NT01012 | 10 x 1.2 mL Positive |

Optitrol NAT HBV Screening



CE 2797

en-GB

| | | | | | | | | | | | |
|-------------------------------------|-------------------------------------|---|--------------------------|-----------------|------------------|-------------------------|----------------------|----------------------------------|---------------------|--------------|----------------------------|
| REF Catalog Number | CE European Conformity | IVD For <i>In-Vitro</i> Diagnostic | LOT Lot Number | Use by Date | Product Logo | Warning / Attention | Biological risks | Consult Instructions for Use | Manufactured by | Importer | Temperature Limitation |
| CONTROL+ Positive Control | CONTROL- Negative Control | EU REP Authorized Representative European Union | | | | | | | | | |

EU REP MediMark Europe Sarl.
11 rue Emile Zola
38100 Grenoble. FRANCE
+33 (0) 4 76 86 43 22
info@medimark-europe.com

LGC Clinical Diagnostics, Inc. | 37 Birch Street, Milford, MA 01757 USA

Phone: +1 508.244.6400 | CDx-Info@LGCGroup.com

